TMED - Trimedyne, Inc.

Other OTC - Other OTC Delayed Price. Currency in USD
8.45
0.00 (0.00%)
At close: 3:04PM EDT
Stock chart is not supported by your current browser
Previous Close8.45
Open0.00
Bid0.00 x 0
Ask0.00 x 0
Day's Range0.00 - 0.00
52 Week Range
Volume0
Avg. Volume29
Market Cap1.042M
Beta (3Y Monthly)-2.88
PE Ratio (TTM)N/A
EPS (TTM)-4.88
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Trade prices are not sourced from all markets
  • GlobeNewswire3 months ago

    Trimedyne Reports Its Financial Results for the Quarter Ended on June 30, 2018

    TRIMEDYNE, INC. (OTCPINK “TMED”) today reported its financial results for its quarter ended on June 30, 2018. For the quarter ended June 30, 2018, Trimedyne had revenues of $1,597,000, an increase of 61% from revenues of $990,000 for the prior year quarter.  The net income for the current quarter of $46,000 or $0.38 per share, as compared to a net loss of $3,000 or $(0.02) per share for the prior year quarter, is a considerable improvement, which was primarily the result of an increase of export sales revenue. Revenues for the nine-month period ended June 30, 2018, were $4,483,000, an increase of 40% from revenues of $3,203,000 for the prior year nine-month period.  The net income for the current nine-month period was $156,000 or $1.27 per share, as compared to a net loss of $259,000 or $(2.11) per share for the prior year nine-month period, is also a considerable improvement, which again was primarily the result of an increase of export sales revenue.

  • We're sorry this is all we were able to find about this topic.